Karyopharm to Present at the Leerink Partners 5th Annual Global Healthcare Conference

NEWTON, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinicalstage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming Leerink Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:30 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at <u>http://investors.karyopharm.com/events.cfm</u>. A replay of the webcast will be archived on the company's website for 30 days following the presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE[™] compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent activity against a variety of human cancers, SINE[™] compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit <u>www.karyopharm.com</u>.

Contact:

Justin Renz (617) 658-0574 jrenz@karyopharm.com

Gina Nugent (617) 460-3579 nugentcomm@aol.com

https://investors.karyopharm.com/2016-02-03-Karyopharm-to-Present-at-the-Leerink-Partners-5th-Annual-Global-Healthcare-Conference